Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/4101

Title: The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks
Authors: van Staa, Tjeerd-Peter
Kanis, John A.
Boonen, Annelies
Leufkens, Hubert G. M.
Cooper, Cyrus
Issue Date: 2007
Citation: VALUE IN HEALTH, 10(5). p. 348-357
Abstract: Objectives: Cost-effectiveness analyses are routinely based on data from group averages, restricting its generalizibility to those with below- or above-average risk. A pharmaco-economic model that used individualized risks for fractures was developed in order to take into account patient heterogeneity. Methods: Data were obtained from The Health Improvement Network research database of general practitioners, comprising a UK general population of women aged more than 50 years (N = 330,000). Mortality and hip, vertebral, and other osteoporotic fracture risks for each individual were estimated by age, body mass index (BMI), smoking, and other clinical risk factors. Estimates on costs, EuroQol (EQ-5D) utilities, and treatment efficacy were obtained from a UK national report (the National Institute for Clinical Excellence) and outcomes were simulated over a 10-year period. Results: It was found that the cost per quality-adjusted life-year (QALY) gained was lower in elderly women and inwomen with fracture history. There was a large variability in the cost-effectiveness with baseline fracture risk and with clinical risk factors. Patients with low BMI (< 20) had considerable better cost-effectiveness than patients with high BMI (>= 26). Using a cost-acceptability ratio of 30k pound per QALY gained, bisphosphonate treatment became cost-effective for patients with a 5-year risk of 9.3% (95% confidence interval [CI] 8.0-10.5%) for osteoporotic fractures and of 2.1% (95% CI 1.5-2.7%) for hip fractures. Including bone mineral density in the risk assessment, the cost per QALY gained was 35k pound in women at age 60 with a fracture history and a T-score of -2.5 (at age 80, this was 3k) pound. Conclusions: A pharmacoeconomic model based on individual long-term risks of fracture improves the selection of postmenopausal women for cost-effective treatment with bisphosphonates.
Notes: Univ Utrecht, Inst Pharmaceut Sci, Dept Pharmacoepidemiol, NL-3508 TB Utrecht, Netherlands. Univ Southampton, Southampton, Hants, England. Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England. State Univ Limburg Hosp, NL-6201 BX Maastricht, Netherlands. Limburgs Univ Ctr, Diepenbeek, Belgium.van Staa, TP, Univ Utrecht, Inst Pharmaceut Sci, Dept Pharmacoepidemiol, NL-3508 TB Utrecht, Netherlands.t.p.vanstaa@uu.nl
URI: http://hdl.handle.net/1942/4101
DOI: 10.1111/j.1524-4733.2007.00188.x
ISI #: 000249828900006
ISSN: 1098-3015
Category: A1
Type: Journal Contribution
Validation: ecoom, 2008
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.